Zoetis completes acquisition of Nexvet BiopharmaAugust 8, 2017Zoetis Inc., manufacturer of veterinary vaccines and medicines for veterinarians, livestock producers, farmers, and pet owners, announced the completion of its $85 million acquisition of Nexvet Biopharma, a Tullamore, Ireland-based company that manufactures monoclonal antibodies (mAb) for companion animal pain management.
SPONSORED CONTENTFind success with your parvovirus protocolDiscover our Canine Parvovirus Monoclonal Antibody: puppies treated with CPMA experienced a 93% real-world survival rate, and were able to head home from the clinic almost two days earlier.1,2 + Read More
